ArticleBMC urology2025
The role of three-dimensional reconstruction in partial nephrectomy for ipsilateral multifocal renal tumors: a multicenter retrospective study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Automated Renal Tumor Segmentation in Computed Tomography Images Using a Global Attention-Based DeepLabV3+ Model: Algorithm Development and Validation.JMIR medical informatics · 2026Article
- Application value of three-dimensional visualization imaging technology in laparoscopic partial nephrectomy for complex renal tumors.Pakistan journal of medical sciences · 2026Article
- Surgical Determinants of Outcomes in Partial Nephrectomy: a Contemporary Review.Current urology reports · 2026Review
- Impact of three-dimensional reconstruction in preoperative planning for partial nephrectomy: A prospective study.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to evaluate the clinical impact of three-dimensional (3D) reconstruction in partial nephrectomy for ipsilateral multifocal renal tumors (MIRTs), focusing on surgical precision, ischemia management, and postoperative outcomes.
methodsA retrospective analysis was performed on 56 MIRTs patients who underwent PN at two hospitals. Patients were divided into two groups: Group A (33 patients) received standard preoperative CT scans, while Group B (23 patients) underwent 3D reconstruction. Surgical data, including operative time, blood loss, ischemia time, and complications, were compared. Renal function was assessed using serum creatinine and eGFR levels preoperatively and postoperatively.
resultsBaseline demographics, including age, body mass index, preoperative hemoglobin levels, and tumor characteristics (size, multifocality), showed no significant intergroup differences (p > 0.05). The 3D reconstruction group demonstrated a 2.2 days reduction in hospital stay (9.43 vs. 11.63 days, p = 0.025) and achieved 100% adherence to preoperative surgical plans (vs. 81.9% in the 2D group, p = 0.037). Operative metrics, including operative time, estimated blood loss, ischemia time, and rates of collecting system injury, showed no significant differences (p > 0.05). Safety outcomes, such as conversion to radical nephrectomy (13.0% vs. 21.2%) and transfusion rates (8.6% vs. 9.1%), were comparable (p > 0.05). Postoperative renal function preservation, assessed by ΔeGFR and ΔSCr, also revealed no intergroup disparities (p > 0.05).
conclusionThree-dimensional reconstruction technology enhances surgical precision and adherence to preoperative plans. It can be considered as a transformative tool in nephron-sparing surgery due to its potential to redefine standards for managing multifocal renal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.